Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials
Author:
Funder
The National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/article/10.1007/s00432-018-2664-y/fulltext.html
Reference44 articles.
1. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J et al (2013) Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14:1307–1316
2. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G et al (2017a) Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35:40–47
3. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS et al (2017b) Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol 71(2):151–154
4. Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T et al (2016) Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11). Prostate 76:1519–1527
5. Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B (2017) Abiraterone or enzalutamide in advanced castration-resistant prostate cancer: an indirect comparison. Prostate 77:639–646
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-11-22
2. Development and verification of a newly established cuproptosis-associated lncRNA model for predicting overall survival in uterine corpus endometrial carcinoma;Translational Cancer Research;2023-08
3. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset;Urologic Oncology: Seminars and Original Investigations;2022-08
4. Novel synthesis of 1,3,4 oxadiazole derivatives poly (maleimide-co-methyl acrylate) with some carboxylic acids and their biological activity;EURASIAN CHEM COMMUN;2022
5. Design, molecular docking studies and ADME prediction of 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives as CYP51 inhibitor for antimicrobial activity;Current Trends in Pharmacy and Pharmaceutical Chemistry;2022-05-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3